AZN Share Price

Open 34.13 Change Price %
High 34.19 1 Day -0.49 -1.43
Low 33.81 1 Week -0.05 -0.15
Close 33.85 1 Month 2.99 9.69
Volume 2555256 1 Year 3.97 13.29
52 Week High 35.04
52 Week Low 25.55
AZN Important Levels
Resistance 2 34.20
Resistance 1 34.06
Pivot 33.95
Support 1 33.64
Support 2 33.50
NYSE USA Most Active Stocks
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
SE 40.68 -0.78%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
WSH 47.18 -2.86%
JNS 14.17 -0.56%
XLS 24.66 -0.64%
More..
NYSE USA Top Gainers Stocks
POM 26.93 26.79%
POM 26.93 26.79%
GLF 0.34 25.93%
GLF 0.34 25.93%
FNP 35.24 12.02%
FNP 35.24 12.02%
STRI 0.20 11.11%
DMD 6.35 9.48%
DMD 6.35 9.48%
GNI 8.10 9.02%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Astrazeneca PLC (NYSE: AZN)

AZN Technical Analysis 5
As on 26th May 2017 AZN Share Price closed @ 33.85 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 30.29 & Strong Buy for SHORT-TERM with Stoploss of 31.26 we also expect STOCK to react on Following IMPORTANT LEVELS.
AZN Target for May
1st Target up-side 31.21
2nd Target up-side 31.89
3rd Target up-side 32.57
1st Target down-side 29.29
2nd Target down-side 28.61
3rd Target down-side 27.93
AZN Other Details
Segment EQ
Market Capital 58447040512.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website http://www.astrazeneca.com
AZN Address
AZN
2 Kingdom Street
London, W2 6BD
United Kingdom
Phone: 44 20 7604 8000
Fax: 44 20 7604 8151
AZN Latest News
Interactive Technical Analysis Chart Astrazeneca PLC ( AZN NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Astrazeneca PLC
AZN Business Profile
AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. and FibroGen, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.